Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 2503 in Advanced Pancreatic Cancer
NCT00005594Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2000
- Primary completion
- Dec 2000
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of H-Ras antisense oligodeoxynucleotide ISIS 2503 in pancreatic cancer (PC), sponsored by University of Alabama at Birmingham. Primary endpoints: Objective Response Rate at 24 weeks and Time to Tumor Progression at 24 weeks. Started Jul 2000; status: completed.
02
Drugs
H-Ras antisense oligodeoxynucleotide ISIS 2503
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00005594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005594.